Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

BioCorRx (BICX) Research & Development (2017 - 2025)

BioCorRx's Research & Development history spans 9 years, with the latest figure at $1.0 million for Q3 2025.

  • For Q3 2025, Research & Development rose 118.34% year-over-year to $1.0 million; the TTM value through Sep 2025 reached $1.7 million, up 29.68%, while the annual FY2024 figure was $1.5 million, 66.42% up from the prior year.
  • Research & Development for Q3 2025 was $1.0 million at BioCorRx, up from $296860.0 in the prior quarter.
  • Across five years, Research & Development topped out at $1.0 million in Q3 2025 and bottomed at $123262.0 in Q2 2021.
  • The 5-year median for Research & Development is $286962.0 (2023), against an average of $363302.3.
  • The largest annual shift saw Research & Development tumbled 90.84% in 2021 before it surged 210.68% in 2022.
  • A 5-year view of Research & Development shows it stood at $234423.0 in 2021, then skyrocketed by 128.69% to $536104.0 in 2022, then tumbled by 76.07% to $128295.0 in 2023, then skyrocketed by 112.43% to $272543.0 in 2024, then skyrocketed by 268.62% to $1.0 million in 2025.
  • Per Business Quant, the three most recent readings for BICX's Research & Development are $1.0 million (Q3 2025), $296860.0 (Q2 2025), and $161919.0 (Q1 2025).